What is Lilly Eli & Co's earnings per share (EPS)?

Lilly Eli & Co (LLY) reported diluted earnings per share of $22.95 for fiscal year 2025. This represents a 96.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lilly Eli & Co Financials

LLY

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Lilly Eli & Co (LLY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LLY FY2025 2026-04-30

Scale is amplifying profitability: Eli Lilly turned rising sales into much richer margins while still funding heavy reinvestment.

Between FY2024 and FY2025, receivables and inventory absorbed about $12.9B of additional capital, showing that faster growth is tying more cash up inside the operating cycle. That helps explain why operating cash flow reached $16.8B while net income was $20.6B, so the earnings surge was real but not fully cash-converted in the same year.

Margin expansion was not driven by starving the pipeline: gross margin climbed from 74.2% in FY2021 to 83.0% in FY2025. At the same time, R&D spending nearly doubled from $6.9B to $13.3B, pointing to a business whose incremental revenue is arriving with far lower cost absorption, not just lower ambition.

Leverage is still meaningful, but the capital structure became less stretched as debt-to-equity improved from 2.0x in FY2024 to 1.5x in FY2025. Liquidity also eased, with the current ratio moving from 0.9x in FY2023 to 1.6x in FY2025, so recent growth strengthened the short-term cushion instead of only enlarging the asset base.

Financial Health Signals

Financial Profile 49/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Lilly Eli & Co's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

Lilly Eli & Co's revenue surged 44.7% year-over-year to $65.2B, reflecting rapid business expansion. This strong growth earns a score of 97/100.

Leverage

Lilly Eli & Co carries a low D/E ratio of 1.54, meaning only $1.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Lilly Eli & Co's current ratio of 1.58 is below the typical benchmark, resulting in a score of 27/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Returns

100

Lilly Eli & Co earns a strong 77.8% return on equity (ROE), meaning it generates $78 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 74.2% the prior year.

Piotroski F-Score Strong

7/9

Lilly Eli & Co passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.81x

For every $1 of reported earnings, Lilly Eli & Co generates $0.81 in operating cash flow ($16.8B OCF vs $20.6B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$65.2B

YoY+44.7%

5Y CAGR+21.6%

10Y CAGR+12.6%

Lilly Eli & Co generated $65.2B in revenue in fiscal year 2025. This represents an increase of 44.7% from the prior year.

EBITDA

N/A

Net Income

$20.6B

YoY+94.9%

5Y CAGR+27.2%

10Y CAGR+24.0%

Lilly Eli & Co reported $20.6B in net income in fiscal year 2025. This represents an increase of 94.9% from the prior year.

EPS (Diluted)

$22.95

YoY+96.0%

5Y CAGR+27.6%

10Y CAGR+26.1%

Lilly Eli & Co earned $22.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 96.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.3B

YoY+122.4%

5Y CAGR+14.7%

10Y CAGR+7.1%

Lilly Eli & Co held $7.3B in cash against $40.9B in long-term debt as of fiscal year 2025.

Dividends Per Share

$6.23

YoY+15.4%

5Y CAGR+15.2%

Lilly Eli & Co paid $6.23 per share in dividends in fiscal year 2025. This represents an increase of 15.4% from the prior year.

Shares Outstanding

943M

YoY-0.5%

5Y CAGR-0.3%

10Y CAGR-1.6%

Lilly Eli & Co had 943M shares outstanding in fiscal year 2025. This represents a decrease of 0.5% from the prior year.

Margins & Returns

Gross Margin

83.0%

YoY+1.7pp

5Y CAGR+5.4pp

10Y CAGR+8.3pp

Lilly Eli & Co's gross margin was 83.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the prior year.

Operating Margin

N/A

Net Margin

31.7%

YoY+8.2pp

5Y CAGR+6.4pp

10Y CAGR+19.6pp

Lilly Eli & Co's net profit margin was 31.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.2 percentage points from the prior year.

Return on Equity

77.8%

YoY+3.6pp

5Y CAGR-32.0pp

10Y CAGR+61.3pp

Lilly Eli & Co's ROE was 77.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.3B

YoY+21.3%

5Y CAGR+17.4%

10Y CAGR+10.8%

Lilly Eli & Co invested $13.3B in research and development in fiscal year 2025. This represents an increase of 21.3% from the prior year.

Share Buybacks

$4.1B

YoY+64.3%

5Y CAGR+52.4%

10Y CAGR+18.5%

Lilly Eli & Co spent $4.1B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 64.3% from the prior year.

Capital Expenditures

N/A

LLY Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$65.2B+44.7%	$45.0B+32.0%	$34.1B+19.6%	$28.5B+0.8%	$28.3B+15.4%	$24.5B
Cost of Revenue	$11.1B+31.3%	$8.4B+18.9%	$7.1B+6.8%	$6.6B-9.3%	$7.3B+33.4%	$5.5B
Gross Profit	$54.1B+47.8%	$36.6B+35.4%	$27.0B+23.4%	$21.9B+4.3%	$21.0B+10.2%	$19.1B
R&D Expenses	$13.3B+21.3%	$11.0B+18.0%	$9.3B+29.5%	$7.2B+3.8%	$6.9B+16.0%	$6.0B
SG&A Expenses	$11.1B+29.1%	$8.6B+16.1%	$7.4B+15.0%	$6.4B+0.1%	$6.4B+5.1%	$6.1B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$895.0M+14.6%	$781.0M+60.7%	$485.9M+46.5%	$331.6M-2.4%	$339.8M-5.5%	$359.6M
Income Tax	$5.1B+143.6%	$2.1B+59.1%	$1.3B+134.0%	$561.6M-2.1%	$573.8M-44.6%	$1.0B
Net Income	$20.6B+94.9%	$10.6B+102.1%	$5.2B-16.1%	$6.2B+11.9%	$5.6B-9.9%	$6.2B
EPS (Diluted)	$22.95+96.0%	$11.71+101.9%	$5.80-15.9%	$6.90+12.7%	$6.12-9.9%	$6.79

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$19.8B+2.6%	$19.3B+9.6%	$17.6B+13.1%	$15.6B+22.2%	$12.7B-5.9%	$13.5B+18.3%	$11.4B+1.2%	$11.3B
Cost of Revenue	$3.6B+6.1%	$3.4B+12.1%	$3.0B+22.9%	$2.4B+10.0%	$2.2B-7.4%	$2.4B+10.7%	$2.2B0.0%	$2.2B
Gross Profit	$16.2B+1.9%	$15.9B+9.1%	$14.6B+11.3%	$13.1B+24.8%	$10.5B-5.6%	$11.1B+20.1%	$9.3B+1.5%	$9.1B
R&D Expenses	$3.5B-7.7%	$3.8B+9.7%	$3.5B+3.9%	$3.3B+22.0%	$2.7B-9.6%	$3.0B+10.6%	$2.7B+0.8%	$2.7B
SG&A Expenses	$2.9B-6.3%	$3.1B+14.3%	$2.7B-0.4%	$2.8B+11.5%	$2.5B+1.8%	$2.4B+15.5%	$2.1B-0.8%	$2.1B
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$332.0M+49.1%	$222.7M+24.0%	$179.6M-27.9%	$249.0M+2.2%	$243.7M+8.3%	$225.1M+16.8%	$192.7M+5.0%	$183.6M
Income Tax	$1.5B-10.7%	$1.6B-1.3%	$1.6B+47.9%	$1.1B+60.1%	$697.0M+10.9%	$628.5M+1.7%	$618.1M+12.3%	$550.2M
Net Income	$7.4B+11.4%	$6.6B+18.9%	$5.6B-1.4%	$5.7B+105.2%	$2.8B-37.4%	$4.4B+354.5%	$970.3M-67.3%	$3.0B
EPS (Diluted)	$8.26	N/A	$6.21-1.3%	$6.29+105.6%	$3.06	N/A	$1.07-67.4%	$3.28

LLY Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$112.5B+42.9%	$78.7B+23.0%	$64.0B+29.3%	$49.5B+1.4%	$48.8B+4.7%	$46.6B
Current Assets	$55.6B+69.9%	$32.7B+27.3%	$25.7B+42.7%	$18.0B-2.3%	$18.5B+5.7%	$17.5B
Cash & Equivalents	$7.3B+122.4%	$3.3B+15.9%	$2.8B+36.4%	$2.1B-45.9%	$3.8B+4.4%	$3.7B
Inventory	$13.7B+81.1%	$7.6B+31.5%	$5.8B+33.9%	$4.3B+10.9%	$3.9B-2.4%	$4.0B
Accounts Receivable	$17.8B+61.4%	$11.0B+21.1%	$9.1B+31.8%	$6.9B+3.3%	$6.7B+13.6%	$5.9B
Goodwill	$5.9B+2.2%	$5.8B+16.8%	$4.9B+21.3%	$4.1B+4.7%	$3.9B+3.3%	$3.8B
Total Liabilities	$85.9B+33.4%	$64.4B+21.1%	$53.2B+37.1%	$38.8B-2.5%	$39.8B-2.8%	$41.0B
Current Liabilities	$35.2B+24.1%	$28.4B+4.0%	$27.3B+59.3%	$17.1B+13.9%	$15.1B+20.6%	$12.5B
Long-Term Debt	$40.9B+43.3%	$28.5B+55.7%	$18.3B+24.3%	$14.7B-4.0%	$15.3B-7.5%	$16.6B
Total Equity	$26.5B+85.9%	$14.3B+32.5%	$10.8B+1.1%	$10.6B+18.6%	$9.0B+59.2%	$5.6B
Retained Earnings	$24.5B+80.7%	$13.5B+31.3%	$10.3B+2.7%	$10.0B+12.1%	$9.0B+14.4%	$7.8B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$116.6B+3.6%	$112.5B-2.1%	$114.9B+13.9%	$100.9B+12.9%	$89.4B+13.6%	$78.7B+4.1%	$75.6B+5.2%	$71.9B
Current Assets	$54.8B-1.4%	$55.6B-10.4%	$62.1B+24.5%	$49.9B+20.8%	$41.3B+26.0%	$32.7B+4.2%	$31.4B+4.0%	$30.2B
Cash & Equivalents	$5.3B-27.3%	$7.3B-25.8%	$9.8B+190.1%	$3.4B+9.1%	$3.1B-5.3%	$3.3B-3.0%	$3.4B+4.5%	$3.2B
Inventory	$14.5B+5.7%	$13.7B+12.8%	$12.2B+10.6%	$11.0B+18.3%	$9.3B+22.7%	$7.6B+1.7%	$7.5B+15.1%	$6.5B
Accounts Receivable	$18.4B+3.8%	$17.8B+10.3%	$16.1B+13.7%	$14.2B+17.7%	$12.0B+9.4%	$11.0B+6.9%	$10.3B-6.6%	$11.0B
Goodwill	$6.1B+3.9%	$5.9B0.0%	$5.9B+2.2%	$5.8B0.0%	$5.8B0.0%	$5.8B0.0%	$5.8B0.0%	$5.8B
Total Liabilities	$85.4B-0.7%	$85.9B-5.7%	$91.1B+10.3%	$82.6B+12.3%	$73.6B+14.2%	$64.4B+5.0%	$61.4B+5.2%	$58.3B
Current Liabilities	$36.6B+4.0%	$35.2B-12.2%	$40.1B+2.9%	$39.0B+29.8%	$30.1B+6.0%	$28.4B+15.0%	$24.7B-9.0%	$27.1B
Long-Term Debt	$39.4B-3.7%	$40.9B0.0%	$40.9B+19.6%	$34.2B-0.9%	$34.5B+20.9%	$28.5B-1.8%	$29.0B+22.4%	$23.7B
Total Equity	$31.2B+17.6%	$26.5B+11.5%	$23.8B+30.2%	$18.3B+15.9%	$15.8B+10.5%	$14.3B+0.2%	$14.2B+5.0%	$13.6B
Retained Earnings	$29.5B+20.6%	$24.5B+10.0%	$22.3B+28.1%	$17.4B+15.1%	$15.1B+11.5%	$13.5B-0.6%	$13.6B+3.4%	$13.2B

LLY Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$16.8B+90.7%	$8.8B+108.0%	$4.2B-44.1%	$7.6B+3.0%	$7.4B+13.3%	$6.5B
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$11.0B-18.0%	-$9.3B-30.0%	-$7.2B-90.1%	-$3.8B-31.2%	-$2.9B-26.9%	-$2.3B
Financing Cash Flow	-$2.2B-279.9%	$1.2B-64.8%	$3.5B+164.7%	-$5.4B-30.9%	-$4.1B-31.7%	-$3.1B
Dividends Paid	$5.4B+15.0%	$4.7B+15.0%	$4.1B+15.1%	$3.5B+14.5%	$3.1B+14.9%	$2.7B
Share Buybacks	$4.1B+64.3%	$2.5B+233.3%	$750.0M-50.0%	$1.5B+20.0%	$1.3B+150.0%	$500.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$5.3B+65.4%	$3.2B-63.5%	$8.8B+186.3%	$3.1B+85.3%	$1.7B-32.7%	$2.5B-33.4%	$3.7B+153.2%	$1.5B
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$3.9B-39.7%	-$2.8B+6.0%	-$3.0B-62.6%	-$1.8B+45.3%	-$3.4B-74.5%	-$1.9B+52.0%	-$4.0B-82.1%	-$2.2B
Financing Cash Flow	-$3.5B-20.5%	-$2.9B-642.1%	$531.0M+142.6%	-$1.2B-190.2%	$1.4B+712.0%	-$225.5M-206.7%	$211.3M-86.4%	$1.6B
Dividends Paid	$1.5B+15.1%	$1.3B0.0%	$1.3B-0.2%	$1.3B+0.1%	$1.3B+15.2%	$1.2B-0.2%	$1.2B-0.2%	$1.2B
Share Buybacks	$2.4B+56.3%	$1.5B+112.9%	$708.1M+2.3%	$692.2M-42.3%	$1.2B-41.6%	$2.1B+360.4%	$446.1M	$0

LLY Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	83.0%+1.7pp	81.3%+2.1pp	79.3%+2.5pp	76.8%+2.6pp	74.2%-3.5pp	77.7%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	31.7%+8.2pp	23.5%+8.2pp	15.4%-6.5pp	21.9%+2.2pp	19.7%-5.5pp	25.2%
Return on Equity	77.8%+3.6pp	74.2%+25.6pp	48.6%-10.0pp	58.6%-3.5pp	62.2%-47.6pp	109.8%
Return on Assets	18.4%+4.9pp	13.5%+5.3pp	8.2%-4.4pp	12.6%+1.2pp	11.4%-1.8pp	13.3%
Current Ratio	1.58+0.4	1.15+0.2	0.94-0.1	1.05-0.2	1.23-0.2	1.40
Debt-to-Equity	1.54-0.5	2.00+0.3	1.70+0.3	1.38-0.3	1.71-1.2	2.94
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	81.9%-0.6pp	82.5%-0.4pp	82.9%-1.4pp	84.3%+1.7pp	82.5%+0.3pp	82.2%+1.2pp	81.0%+0.2pp	80.8%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	37.4%+2.9pp	34.4%+2.7pp	31.7%-4.7pp	36.4%+14.7pp	21.7%-10.9pp	32.6%+24.1pp	8.5%-17.8pp	26.3%
Return on Equity	23.7%-1.3pp	25.0%+1.6pp	23.5%-7.5pp	31.0%+13.5pp	17.5%-13.4pp	30.9%+24.1pp	6.8%-15.1pp	21.9%
Return on Assets	6.3%+0.4pp	5.9%+1.0pp	4.9%-0.8pp	5.6%+2.5pp	3.1%-2.5pp	5.6%+4.3pp	1.3%-2.9pp	4.1%
Current Ratio	1.50-0.1	1.58+0.0	1.55+0.3	1.28-0.1	1.37+0.2	1.15-0.1	1.27+0.2	1.11
Debt-to-Equity	1.26-0.3	1.54-0.2	1.72-0.2	1.87-0.3	2.19+0.2	2.00-0.0	2.04+0.3	1.75
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Johnson & Johnson JNJ

$564.1B

$381.1B

$290.1B

$290.0B

$199.3B

Frequently Asked Questions

What is Lilly Eli & Co's annual revenue?

Lilly Eli & Co (LLY) reported $65.2B in total revenue for fiscal year 2025. This represents a 44.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lilly Eli & Co's revenue growing?

Lilly Eli & Co (LLY) revenue grew by 44.7% year-over-year, from $45.0B to $65.2B in fiscal year 2025.

Is Lilly Eli & Co profitable?

Yes, Lilly Eli & Co (LLY) reported a net income of $20.6B in fiscal year 2025, with a net profit margin of 31.7%.

How much debt does Lilly Eli & Co have?

As of fiscal year 2025, Lilly Eli & Co (LLY) had $7.3B in cash and equivalents against $40.9B in long-term debt.

What is Lilly Eli & Co's gross margin?

Lilly Eli & Co (LLY) had a gross margin of 83.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lilly Eli & Co's net profit margin?

Lilly Eli & Co (LLY) had a net profit margin of 31.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Lilly Eli & Co pay dividends?

Yes, Lilly Eli & Co (LLY) paid $6.23 per share in dividends during fiscal year 2025.

What is Lilly Eli & Co's return on equity (ROE)?

Lilly Eli & Co (LLY) has a return on equity of 77.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lilly Eli & Co's operating cash flow?

Lilly Eli & Co (LLY) generated $16.8B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lilly Eli & Co's total assets?

Lilly Eli & Co (LLY) had $112.5B in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Lilly Eli & Co spend on research and development?

Lilly Eli & Co (LLY) invested $13.3B in research and development during fiscal year 2025.

Does Lilly Eli & Co buy back shares?

Yes, Lilly Eli & Co (LLY) spent $4.1B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Lilly Eli & Co have outstanding?

Lilly Eli & Co (LLY) had 943M shares outstanding as of fiscal year 2025.

What is Lilly Eli & Co's current ratio?

Lilly Eli & Co (LLY) had a current ratio of 1.58 as of fiscal year 2025, which is generally considered healthy.

What is Lilly Eli & Co's debt-to-equity ratio?

Lilly Eli & Co (LLY) had a debt-to-equity ratio of 1.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lilly Eli & Co's return on assets (ROA)?

Lilly Eli & Co (LLY) had a return on assets of 18.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lilly Eli & Co's Piotroski F-Score?

Lilly Eli & Co (LLY) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lilly Eli & Co's earnings high quality?

Lilly Eli & Co (LLY) has an earnings quality ratio of 0.81x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Lilly Eli & Co?

Lilly Eli & Co (LLY) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.